{rfName}

Indexed in

License and Use

Icono OpenAccess

Citations

13

Altmetrics

Analysis of institutional authors

Jiménez-Vicente CAuthorGuardia-Torrelles, AAuthorPérez-Valencia AiAuthorMartínez-Roca AAuthorCastaño-Díez SAuthorGuijarro FAuthorCortés-Bullich AAuthorTriguero AAuthorDíaz-Beyá MAuthorEsteve JCorresponding Author

Share

December 5, 2024
Publications
>
Article
Sí

Clinical management of patients diagnosed with acute myeloid leukemia treated with venetoclax in combination with hypomethylating agents after achieving a response: a real-life study

Publicated to: Annals Of Hematology. 103 (10): 4033-4043 - 2024-10-01 103(10), DOI: 10.1007/s00277-024-05923-5

Authors: Jiménez-Vicente, C; Guardia-Torrelles, A; Pérez-Valencia, AI; Martínez-Roca, A; Castaño-Diez, S; Guijarro, F; Cortés-Bullich, A; Merchán, B; Triguero, A; Hernández, I; Brillembourg, H; Munárriz, D; Zugasti, I; Fernández-Avilés, F; Diaz-Beyá, M; Esteve, J

Affiliations

Hosp Clin Barcelona, Hematol Dept, Villarroel 170, Barcelona 08036, Spain - Author
Hosp Clin Barcelona, Pathol Dept, Hemopathol Unit, Barcelona, Spain - Author
Inst Invest Biomed August Pi i Sunyer IDIBAPS, Barcelona, Spain - Author
Univ Barcelona, Barcelona, Spain - Author
See more

Abstract

Although there is an approved indication for venetoclax and hypomethylating agents (VenHMA) and its use in different AML settings will be expanded in the following years, the management of the adverse events (AEs) lacks of harmonized algorithms during treatment of these patients. We have studied the incidence of relevant AEs of 43 patients who achieved a response to VenHMA and its management. Median overall survival of our cohort was 19 months. No patients discontinued treatment due to AEs after C3D1, Regarding severe AEs, high rates of grade 4 neutropenia (97.6%) and grade 4 thrombocytopenia (65.1%) were observed. Severe infectious AEs rate was 16%. Due to severe myelotoxicity, most patients required a progressive dose reduction of both venetoclax and hypomethylating agents during follow-up, being 87.8% at C6D1. Transfusional dependence rate was 91% and G-CSF was prescribed to 86% of the patients. Finally, there was not a significant difference in hemoglobin, platelets and absolute neutrophil count after achieving complete response comparing paired samples during follow-up, although cytopenia rate was high during initial follow-up. We conclude that dose reduction of VenHMA after achieving a response in patients diagnosed with AML is required in most patients and essential to avoid prolonged cytopenia-related adverse events and a rapid and standardized method on how to perform it might decrease the AEs rate.

Keywords

Absolute neutrophil countAcute myeloid leukemiaAdultAdverseeventAdverseeventsAgedAged, 80 and overAgents affecting metabolismAllogeneic stem cell transplantationAmiodaroneAmlAnemiaAntineoplastic agentAntineoplastic combined chemotherapy protocolsArticleAtrial fibrillationAzacitidineBacterial infectionBone marrow toxicityBridged bicyclo compounds, heterocyclicCelulitisCohort analysisCriteriaCytopeniaCytopeniasDecitabineDrug dose reductionDrug therapyEcog performance statusExperienceFebrile neutropeniaFemaleFollow upFollow-up studiesFused heterocyclic ringsGranulocyte colony stimulating factorHumanHumansHypomethylating agentIncidenceInduction chemotherapyIntensive chemotherapyIsavuconazoleLeukemia, myeloid, acuteMaleManagementMiddle agedMultiple cycle treatmentMyelodysplastic syndromeNeutropeniaNeutrophil countOsteomyelitisOutcomeOverall survivalPlatelet countQuinoline derived antiinfective agentRetrospective studiesRetrospective studySingle-centerSubdural hematomaSulfonamideSulfonamidesThrombocytopeniaTreatment responseTriazole derivativeTumor lysis syndromeUnclassified drugVenetoclaxVery elderly

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Annals Of Hematology due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2024 there are still no calculated indicators, but in 2023, it was in position 45/98, thus managing to position itself as a Q2 (Segundo Cuartil), in the category Hematology. Notably, the journal is positioned en el Cuartil Q2 para la agencia Scopus (SJR) en la categoría Medicine (Miscellaneous).

Independientemente del impacto esperado determinado por el canal de difusión, es importante destacar el impacto real observado de la propia aportación.

Según las diferentes agencias de indexación, el número de citas acumuladas por esta publicación hasta la fecha 2025-12-16:

  • WoS: 4
  • Scopus: 3
  • Europe PMC: 4

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-12-16:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 10.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 10 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 12.
  • The number of mentions on the social network X (formerly Twitter): 17 (Altmetric).

It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

  • The work has been submitted to a journal whose editorial policy allows open Open Access publication.

Leadership analysis of institutional authors

There is a significant leadership presence as some of the institution’s authors appear as the first or last signer, detailed as follows: First Author (Jiménez Vicente, Carlos) and Last Author (Esteve Reyner, Jordi).

the author responsible for correspondence tasks has been Esteve Reyner, Jordi.

Awards linked to the item

No Statement Available